Abstract: The present disclosure relates to methods for inhibiting activation of ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing ?? T cells that express a V?9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.
Type:
Application
Filed:
June 26, 2020
Publication date:
September 1, 2022
Applicants:
The University of Melbourne, Olivia Newton-John Cancer Research Institute, CSL INNOVATION PTY LTD
Inventors:
Andreas BEHREN, Jonathan CEBON, Marc Rigau CORTAL, Thomas Samuel FULFORD, Dale Ian GODFREY, Andrew HAMMET, Simone OSTROUSKA, Con PANOUSIS, Adam Peter ULDRICH
Abstract: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
Type:
Grant
Filed:
July 5, 2018
Date of Patent:
November 2, 2021
Assignees:
Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd., Olivia Newton-John Cancer Research Institute
Inventors:
Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
Abstract: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
Type:
Application
Filed:
September 4, 2019
Publication date:
October 21, 2021
Applicants:
The Regents of the University of California, California Institute of Technology, The Olivia Newton-John Cancer Research Institute
Inventors:
Owen N. Witte, Jami McLaughlin Witte, Antoni Ribas, Lili Yang, Michael T. Bethune, Jonathan Cebon, Katherine Woods, Ashley J. Knights, David Baltimore
Abstract: Method and apparatus of transferring heat from a substance by way of an intermediate compressible fluid in which the heated fluid is compressed during intermittently spaced periods for subsequent cooling, high pressure fluid being fed back into the low pressure side during and immediately after the periods of compression.